Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Boehringer Ingelheim Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (86)
Cancellation by sponsor (46)
Prescription medicine registration (11)
Australian public assessment report (AusPar) (7)
Designation or determination (2)
Prescription medicine decision summary (1)

Date

2025 (4)
2024 (5)
2023 (9)
2022 (3)
2021 (6)
2020 (14)
2019 (2)
2018 (15)
2017 (4)
2016 (14)
2015 (13)
2014 (4)
2013 (14)
2012 (3)
2011 (8)
2010 (5)
2008 (4)
2007 (2)
2003 (1)
2002 (3)
2001 (4)
2000 (3)
1999 (7)
1998 (1)
1996 (1)
1993 (1)
1992 (1)
1991 (2)

Search

Sponsor content

153 result(s) found, displaying 61 to 70

FAVINT RESPIMAT tiotropium 2.5 micrograms/actuation solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
VIRAMUNE XR nevirapine 100 mg extended-release tablet bottle Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 5 mg / 500 mg empagliflozin/metformin hydrochloride 5mg/500mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 5 mg / 850 mg empagliflozin/metformin hydrochloride 5mg/850mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 5 mg / 1000 mg empagliflozin/metformin hydrochloride 5mg/1000mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 12.5 mg / 500 mg empagliflozin/metformin hydrochloride 12.5mg/500mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 12.5 mg / 850 mg empagliflozin/metformin hydrochloride 12.5mg/850mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 12.5 mg / 1000 mg empagliflozin/metformin hydrochloride 12.5mg/1000mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
Boehringer Ingelheim Pty Ltd - Medicine administration kit, oral Cancelled under Section 41GL(d) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
SPIRIVA RESPIMAT; SRIVASSO RESPIMAT; ESOVYND RESPIMAT; FAVINT RESPIMAT (Boehringer Ingelheim Pty Ltd)

26 April 2018

Prescription medicine registration

Active ingredients: tiotropium bromide monohydrate.

Pages

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Page 9
Page 10
Page 11
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.